Professor, Medicine, University Massachusetts Medical School
Hematology
Dr. Doreen B. Brettler, MD
|
|
Give Review
Doreen Brettler practices Hematology. She attended Stanford University School of Medicine. Stanford University School of Medicine is a one of the best medicals schools. Stanford University School of Medicine has a rank of 2 in research and a 25 in primary care She received 1 awards: "Meaningful Use Stage 1 Certification". Doreen B. Brettler, MD has written publications. She has 50 publications published with PubMed. The lastest publication is: 'Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo.' She accepts all Medicare patients.
Publications
- Gene therapy for Hemophilia?
- The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies.
- Long-term nonprogressive infection with human immunodeficiency virus type 1 in a Hemophilia cohort.
- Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T Cell loss: evidence supporting a protective role for CTL in vivo.
- A recombinant circumsporozoite protein vaccine against malaria.
- Inhibitors in congenital haemophilia.
- AIDS-associated non-Hodgkin's Lymphomas as primary and secondary AIDS diagnoses in hemophiliacs. Hemophilia Malignancy Study Group.
- Hemostasis: a practical review of conservative and operative care.
- Anaphylaxis after treatment with recombinant factor VIII.
- Normal Immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection.
- Immune status of human immunodeficiency virus seropositive and seronegative Hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.
- Comprehensive Hemophilia care and home factor infusions.
- Inhibitors of factor VIII: detection and treatment.
- Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.
- Hepatitis C virus transmission by monoclonal purified viral-attenuated factor VIII concentrate.
- Relation of human neutrophil phorbol ester receptor occupancy and NADPH-oxidase activity.
- Analysis of cytomegalovirus and Epstein-Barr virus antibody responses in treated hemophiliacs. Implications for the study of acquired immune deficiency Syndrome.
- Aetiology of AIDS--antibodies to human T-Cell leukaemia virus (type III) in haemophiliacs.
- Epidemiology and clinical impact of hepatitis D virus (delta) infection.
- A long-term study of hemophilic arthropathy of the knee joint on a program of Factor VIII replacement given at time of each hemarthrosis.
- Human immunodeficiency virus isolation studies and antibody testing. Household contacts and sexual partners of persons with Hemophilia.
- Assessment of reproductive risks and intentions by mothers of children with Hemophilia.
- Primary pulmonary hypertension in patients with classic Hemophilia.
- Immunologic aberrations, HIV seropositivity and seroconversion rates in patients with Hemophilia B.
- Hemophiliac immunodeficiency: influence of exposure to factor VIII concentrate, LAV/HTLV-III, and herpesviruses.
- Hemophilia and acquired immune deficiency Syndrome.
- Isolation of human immunodeficiency virus from Hemophiliacs: correlation with clinical symptoms and immunologic abnormalities.
- Delayed cutaneous hypersensitivity reactions in Hemophiliac subjects treated with factor concentrate.
- Factor concentrates for treatment of Hemophilia: which one to choose?
- Proposed protocol for the evaluation of the effect of high purity factor concentrates on the immune System of hemophilia patients.
- The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
- Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies.
- Growth failure as a prognostic indicator for progression to acquired immunodeficiency Syndrome in children with hemophilia.
- Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of Hemophilia A. recombinant Factor VIII Study Group.
- Prevalence of hepatitis C virus antibody in a cohort of Hemophilia patients.
- Low risk for hepatitis C in Hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group.
- Pregnancy in a cohort of long-term partners of human immunodeficiency virus-seropositive Hemophiliacs.
- Comments on the development of inhibitor antibodies in patients using recombinant factor VIII concentrates.
- Deficient human immunodeficiency virus type 1-specific cytotoxic T Cell responses in vertically infected children.
- Haemophilia in the 1990s: report of a joint meeting of the World Health Organization and World Federation of Hemophilia.
- Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector Cell populati...
- Hepatocellular carcinoma in Hemophilia.
- The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study.
- Hemophilia in the 1990s: principles of management and improved access to care.
- Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the Coagulation mechanism in vivo.
- Silent human immunodeficiency virus type 1 infection: a rare occurrence in a high-risk heterosexual population.
- Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator Group.
- Chronic basophilic Leukemia: a rare form of chronic myeloproliferative neoplasm.
- EBV-negative Hodgkin lymphoma in ZAP-70-positive B-cell lymphocytic Leukemia patient.
Schools
Stanford University School Of Medicine
Santa Clara Vly Med Center
Stanford
Peter Bent Brigham Hospital
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
Massachusetts General Hospital -
Brigham and Women's Hospital -
Stanford University -
Santa Clara Valley Medical Center -
Stanford University School of Medicine
Hospital
-
UMass Memorial Medical Center
Drug Facts
| NPI NUMBER | 1710960398 | |
| NPPES Provider LastName | BRETTLER | |
| NPPES Provider FirstName | DOREEN | |
| NPPES Provider ZIPCode | 016052903 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 438.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 92.0 | |
| Percent Opioid Claims | 21.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1710960398 |
| Last Name Of The Provider | BRETTLER |
| First Name Of The Provider | DOREEN |
| View All |
Similar Doctors
|
|
Eswar Tipirneni |
|
|
Dr. Abhishek Tripathi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter Georges, MD |
|
|
Dr. Mary L. Lopresti, DO |
|
|
Dr. James D. O'Shea, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lyndon Kim, MD |
|
|
Dr. Shakeeb A. Yunus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan E. Donohue, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Louis M. Snyder, MD |
|
|
Dr. Muthalagu Ramanathan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Glen D. Raffel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary E. Costanza, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Athanasius A. Anagnostou, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Neil J. Kluger, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajneesh Nath, MD
This Doctor is OpenDoctor Recommended.
|